

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 January 2018 (18.01.2018)



(10) International Publication Number
WO 2018/011420 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/EP2017/067923

(22) International Filing Date:
14 July 2017 (14.07.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1612337.4 15 July 2016 (15.07.2016) GB

(71) Applicant: **ARGENX BVBA** [BE/BE]; Industriepark 7,
9052 Zwijnaarde (BE).

(72) Inventors: **BLANCHETOT, Christophe Frederic Jerome**; c/o argenx BVBA, Industriepark Zwijnaarde 7, Building C, B-9052 Gent (BE). **URSØ, Birgitte**; c/o LEO Pharma A/S, 55, Industriparken, 2750 Ballerup (DK). **SKAK-NIELSEN, Tine**; c/o LEO Pharma A/S, 55, Industriparken, 2750 Ballerup (DK). **BERTELSEN, Malene**; c/o LEO Pharma A/S, 55, Industriparken, 2750 Ballerup (DK). **VAN DER WONING, Sebastian**; c/o argenx BVBA, Industriepark Zwijnaarde 7, Building C, B-9052 Gen (BE). **SAUNDERS, Michael**; c/o argenx BVBA, Industriepark Zwijnaarde 7, Building C, B-9052 Gent (BE). **DE HAARD, Johannes Joseph Wilhelmus**; c/o argenx BVBA, Industriepark Zwijnaarde 7, Building C, B-9052 Gent (BE).

(74) Agent: **BOULT WADE TENNANT**; Verulam Gardens,
70 Gray's Inn Road, London Greater London WC1X 8BT (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-IL-22R ANTIBODIES

Fig.1



(57) Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.

WO 2018/011420 A1